Rexahn Pharmaceuticals, Inc. (REXN)

[DorianGray]

PS: We have three near-term catalysts over the next five months, between now and the end of Q1/15. They are: (1) the safety data from Archexin, (2) the safety data and initial efficacy data from the Phase 1b trial with RX-3117, and (3) the safety data and initial efficacy data from an ongoing Phase 1 trial with our third candidate in development, Supinoxin.